Newsletter   Secure Checkout   View Cart (0 items)  
Search:    Welcome Guest! Save up to 30-40% on most items with our awesome everyday discounts!

HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy) [Hardcover]

Our Price $ 114.10  
Retail Value $ 163.00  
You Save $ 48.90  (30%)  
Item Number 223551  
Buy New $114.10
Out Of Stock!
Currently Out Of Stock
Currently unavailable...

Item description for HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy) by Gerd Schmitz...

HMG-CoA reductase inhibitors (statins) are established drugs for the treatment of hypercholesterolemia. Furthermore, they induce regression of vascular atherosclerosis as well as reduction of cardiovascular-related morbidity and death in patients with and without coronary artery disease. This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. Emphasis is placed on the scientific background to the discoveries and the development of the therapy, including an overview of the current state of knowledge of the drugs. Clinical data are reviewed extensively. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins. It sets the stage for creative thinking among scientists of many disciplines for the accomplishment of our ultimate goals in treating atherosclerosis and its sequelae. This topical volume...

Promise Angels is dedicated to bringing you great books at great prices. Whether you read for entertainment, to learn, or for literacy - you will find what you want at!

Item Specifications...

Pages   151
Est. Packaging Dimensions:   Length: 9.25" Width: 6.75" Height: 0.75"
Weight:   1.27 lbs.
Binding  Hardcover
Release Date   Dec 5, 2002
Publisher   Birkhäuser Basel
ISBN  376436307X  
ISBN13  9783764363079  

Availability  0 units.

More About Gerd Schmitz

Register your artisan biography and upload your photo! Are You The Artisan or Author behind this product?
Improve our customers experience by registering for an Artisan Biography Center Homepage.

Product Categories

1Books > Subjects > Medicine > Basic Science > Immunology
2Books > Subjects > Medicine > Diseases > Cardiovascular
3Books > Subjects > Medicine > General
4Books > Subjects > Medicine > Internal Medicine > Cardiology
5Books > Subjects > Medicine > Internal Medicine > Oncology > Chemotherapy
6Books > Subjects > Medicine > Pharmacology > General
7Books > Subjects > Medicine > Pharmacology > Pharmacy
8Books > Subjects > Professional & Technical > Medical > Basic Sciences > Immunology
9Books > Subjects > Professional & Technical > Medical > Medicine > Internal Medicine > Cardiology
10Books > Subjects > Professional & Technical > Medical > Pharmacology > Pharmacology
11Books > Subjects > Professional & Technical > Medical > Pharmacology > Pharmacy
12Books > Subjects > Professional & Technical > Professional Science > Biological Sciences > Biology > Biology
13Books > Subjects > Science > Biological Sciences > Biology > General

Reviews - What do customers think about HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy)?

Misleading Expertise  Oct 7, 2003
HMG-CoA reductase inhibitors are essentially the statin drugs: atorvastatin (Lipitor™), cerivastatin (Baycol™,
withdrawn 8/01), fluvastatin (Lescol™), lovastatin (Mevacor™), pravastatin (Pravachol™), simvastatin (Zocor™),
pitavastatin and rosuvastatin (Crestor™), which were introduced to lower total cholesterol (TC) levels, and especially
LDL-cholesterol (LDL) levels, ostensibly to prevent coronary heart disease (CVD).

The book consists of 8 chapters by nominally highly qualified authors in the form of review articles of the sort
normally found in medical journals. These are devoted to the pharmacology and supposed benefits of statin drugs.
The writing is in expert medical language and is consistent, well-written, well-edited and very well-referenced, in
quantity if not in quality. The index is inadequate.

All chapters attempt to justify the wide use of the statin drugs to lower TC and LDL by citing references in support
of the claims that high levels have been correlated with cardiovascular disease (pp1,19,35,81,84,99,121,126). Such
claims are unfounded (Ravnskov U, The Cholesterol Myths, Washington, DC, New Trends, 2000).

The supposed benefits of the statins, beyond a large, but meaningless lowering of TC and LDL, are usually given
as lowered relative risks (RR) of mostly non-fatal heart attacks without the slightest indication of the magnitude of the
more meaningful reduction of absolute risk (pp101,103,106,115,122,124,137). This misrepresentation has been
noted (Ravnskov, 2000; Gigerenzer G, Calculated Risks: How to Know When Numbers Deceive You, New York,
NY, Simon & Schuster, 2002). So the usual tout of pravastatin in the WOSCOPS trial of a 22% drop in all-cause
mortality was noted without the information that this was only an 0.9% drop absolute in the 5-year trial period
(p106). The higher all-cause death rates in 2 of the big trials were ignored, as was the higher breast cancer rate (RR
= 1500%) in the CARE trial (Ravnskov, 2000).

Besides cancer, the other side effects of statins listed were incomplete, and should have included myalgia,
myopathy, polyneuropathy, liver and kidney damage, congestive heart failure and amnesia. Side-effects were said to
affect 2% of patients (p115-6) and 2-6% (p123). In fact, a recent review noted side-effects in 20% of patients above
the placebo rate, and no change whatever in the all-cause death rate for atorvastatin (Newman CB, Palmer G,
Silbershatz H, Szarek M. Safety of Atorvastatin Derived from Analysis of 44 Completed Trials in 9,416 Patients.
Am J Cardiol 2003;92:670-6).

Statins decrease the body's production of the essential coenzyme Q-10 and dolichol, among other things. This
was not mentioned as a problem in any chapter. While this was shown in one biochemical diagram (p65), it was not
in another (p82). Low Q-10 levels are strongly associated with congestive heart failure.

"Statins are contra-indicated during pregnancy and breastfeeding. The reason for this is that cholesterol is an
essential component for fetal development, including the synthesis of steroids and cell membranes" (p116). The
authors seem unable to comprehend that cell membranes, steroids and coenzyme Q-10 are needed by all humans.

The rare familial hypercholesterolemia, in which TC > 400 mg/dL, was represented as more deadly than it really
is (p99,111), (Ravnskov, 2000).

There was some recognition that statins operate to lower non-fatal heart attack rates by mechanisms other than
cholesterol lowering, but not that their desirable effect on thromboxane A2 is less than men can obtain with buffered
aspirin (p71), or that the desirable effect of raising nitric oxide (NO) levels is less than one can obtain with the
supplement L-arginine with no side-effects. There was no understanding that these effects of statins are independent
of initial or final TC or LDL levels (Nielsen JV. Serun lipid lowering and risk reduction? Where is the connection?
Br Med J Rapid Response, 19 Nov 01, to Kmietowicz Z. Statins are the new aspirin, Oxford researchers say. Br
Med J 2001;323:1145), and thus there is no way to determine who should be treated, or what the dose should be.

An entire chapter is devoted to the cost-benefits of statin use (p138ff). Since the use of statins for primary
prevention of CVD has been shown to increase all-cause mortality by 1% over a 10-year period (Jackson PR, et al.
Statins for primary prevention: at what coronary risk is safety assured? Br J Pharmacology 2001;52:439-446), and statins
have very little effect in secondary prevention, it would seem that there is no cost-benefit (Kauffman JM, "Do
Hypolipidemic Drugs Lower Medical Expenses?" Pharmacotherapy 2001;22(12),1583-1586).

This book may be of use for a pharmacologist looking for an overview, however narrow in outlook, with literature citations.

---Joel M. Kauffman, 6 Oct 03


Write your own review about HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy)

Ask A Question or Provide Feedback regarding HMG-CoA Reductase Inhibitors (Milestones in Drug Therapy)

Item Feedback and Product Questions
For immediate assistance call 888.395.0572 during the hours of 10am thru 8pm EST Monday thru Friday and a customer care representative will be happy to help you!

Help us continuously improve our service by reporting your feedback or questions below:

I have a question regarding this product
The information above is incorrect or conflicting
The page has misspellings or incorrect grammar
The page did not load correctly in my browser or created an error.

Email Address:
Anti Spam Question. To combat spammers we require that you answer a simple question.
What color is the sky?
Leave This Blank :
Do Not Change This Text :

Add This Product Widget To Your Website

Looking to add this information to your own website? Then use our Product Widget to allow you to display product information in a frame that is 120 pixels wide by 240 pixels high.

    Copy and paste the following HTML into your website and enjoy!

Order toll-free weekdays 10am thru 10pm EST by phone: 1-888-395-0572 (Lines are closed on holidays & weekends.)
Customer Service | My Account | Track My Orders | Return Policy | Request Free Catalog | Email Newsletter

Gift Certificates
RSS Feeds
About Us
Contact Us
Terms Of Use
Privacy Policy